FDA 483 - Novitium Pharma LLC - February 04, 2019

An FDA inspection of Novitium Pharma, Inc. in East Windsor, New Jersey, revealed significant deficiencies in their quality system and laboratory controls. Observations included inadequate assessment and control of changes to approved drug applications, as well as incomplete records for laboratory reference standards. These findings indicate systemic issues with the firm's quality unit procedures and documentation practices.